InMed Pharmaceuticals Inc. (NASDAQ: INM) (‘InMed’ or the ‘Company’), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC (‘BayMedica’), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation.

As previously announced, H.R. 5371, the ‘Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026’ (the ‘Act‘) in its current form and without further amendment, will have a material negative impact on BayMedica. Specifically, certain aspects of BayMedica’s commercial business and its inventory of rare, non-intoxicating cannabinoids would be prohibited under the Act if it becomes effective as planned on November 12, 2026.

On March 4, 2026, after considering all reasonably available options and a broader strategic assessment, the Company’s board of directors (the ‘Board‘) ratified, confirmed and approved the decision of the board of directors of BayMedica to wind down and exit BayMedica’s commercial operations business segment (‘commercial operations‘). BayMedica intends to substantially complete the wind down and exit prior to the end of its fiscal year ending June 30, 2026. During the interim period leading to the completion of operational wind down, BayMedica will continue its commercial operations including sales, marketing, limited manufacturing, and logistics.

Following the wind down of commercial operations, the Company will focus exclusively on advancing its core drug development programs, including INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration, towards IND filings and initial human clinical trials. The Company intends to provide shareholders with an update on its pharmaceutical pipeline in the near term.

Eric A. Adams, Chief Executive Officer of InMed, commented, ‘Following an extensive evaluation of BayMedica’s commercial outlook amid increasing regulatory uncertainty, BayMedica’s leadership determined to wind down its commercial activities. After careful review, the Board agreed that this strategic step is warranted given the current legislative environment and, further, enables InMed to focus its full internal resources on the development and advancement of our proprietary pharmaceutical drug development programs, which have the greatest potential to deliver long-term shareholder value.’

Operational and Financial Impact

The wind down of BayMedica’s commercial operations will be executed in an orderly manner designed to minimize disruption to customers, suppliers, and employees. BayMedica’s management team is developing a transition plan that will be communicated to affected stakeholders, and the Company currently expects the process to be completed within the coming months. BayMedica is expected to incur severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 through the end of this fiscal year ending June 30, 2026. These expenditures are expected to be partially offset by the profits from the sale of BayMedica’s products.

The Company has outlined the current financial implications, including unaudited pro forma consolidated financial information, in a Form 8-K filed with the U.S. Securities and Exchange Commission (the ‘SEC‘) on March 6, 2026. InMed expects to provide additional updates, as appropriate, in future earnings releases and periodic filings with the SEC.

About InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains ‘forward-looking information’ and ‘forward-looking statements’ (collectively, ‘forward-looking information’) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as ‘expects’, ‘anticipates’, ‘believes’, ‘intends’, ‘potential’, ‘possible’, ‘would’ and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, statements about the Act, the impact of the Act on BayMedica, decision of the board members of BayMedica to wind down and exit BayMedica’s commercial operations business segment as well as financial and operational impact on the wind-down of BayMedica commercial operations.

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286536

Nuvau Minerals Inc. (TSXV: NMC,OTC:NMCPF) (the ‘Company’ or ‘Nuvau’) is pleased to announce that it has closed the second and final tranche of its previously announced brokered private placement pursuant to which the Company issued (i) an aggregate of 7,928,523 common shares of the Company (each, a ‘FT Share’) that qualify as ‘flow-through shares’ within the meaning of the Income Tax Act (Canada) (the ‘Tax Act’), at an issue price of $0.90 per FT Share, for gross proceeds of $7,135,670.70, and (ii) an aggregate of 320,000 units of the Company (each, a ‘Unit’), at a price of $0.80 per Unit, for gross proceeds of $256,000 (together, the ‘Offering’). Together with the closing of the first tranche of the Offering on February 25, 2026, the Company has raised an aggregate of $21,368,670.70 in gross proceeds. Each Unit is comprised of one common share of the Company (each, a ‘Common Share’) and one-half of one transferrable common share purchase warrant of the Company (each whole warrant, a ‘Warrant’), with each Warrant entitling the holder thereof to purchase one Common Share at a price of $1.30 per Common Share until February 25, 2029.

The gross proceeds of the Offering will be used by the Company to incur eligible ‘Canadian exploration expenses’ (as defined in the Tax Act), which will qualify as ‘flow-through mining expenditures’ or as ‘flow-through critical mineral mining expenditures’ (‘FTCMME‘) (each as defined in the Tax Act) (the ‘Qualifying Expenditures‘). At least 30% of the Qualifying Expenditures to be renounced to each subscriber of FT Shares will qualify as FTCMME, with certain subscribers being entitled to the renunciation of a higher percentage of Qualifying Expenditures that qualify as FTCMME. All Qualifying Expenditures will be incurred by the Company on or before December 31, 2027, and will be renounced in favour of the subscribers of the FT Shares with an effective date on or before December 31, 2026.

The Offering was co-led by Clarus Securities Inc. and Integrity Capital Group Inc., as co-lead agents and co-lead bookrunners (together, the ‘Agents‘). In consideration for the Agents’ services, the Company paid the Agents a cash commission equal to 6.0% of the gross proceeds of the Offering (the ‘Cash Fee‘), provided that the Company paid a reduced Cash Fee of 3.0% in respect of the gross proceeds raised from sales to purchasers included on a president’s list formed by the Company in consultation with the Agents (the ‘President’s List Purchasers‘). In addition, the Company agreed to issue to the Agents such number of non-transferable compensation options of the Company (the ‘Compensation Options‘) as is equal to 6.0% of the aggregate number of FT Shares and/or Units sold under the Offering; provided that such number of Compensation Options was reduced to 3.0% of number of FT Shares and/or Units sold to President’s List Purchasers. Each Compensation Option entitles the holder thereof to purchase one Unit at a price of $0.80 per Unit at any time and from time to time until March 6, 2029.

In connection with the Offering, a director of the Company subscribed for an aggregate of 444,444 FT Shares for aggregate gross proceeds of $444,444. Each subscription by an ‘insider’ is considered to be a ‘related party transaction’ for the purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101‘). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. Specifically, the Company is exempt from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on section 5.5(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves insiders, is not more than 25% of the Company’s market capitalization. Additionally, the Company is exempt from minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(1)(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves insiders, is not more than 25% of the Company’s market capitalization. The Company did not file a material change report more than 21 days before the expected closing date of the Offering as the details of the Offering and the participation of insiders therein was not settled until shortly prior to the closing of the Offering, and the Company wished to close the Offering on an expedited basis for sound business reasons.

All securities issued under the Offering are subject to a hold period expiring four months and one day from the date hereof. The Offering remains subject to final acceptance of the TSX Venture Exchange.

The securities offered have not been registered under the U.S. Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Nuvau

Nuvau is a Canadian mining company, incorporated under the OBCA, currently in the exploration and development phase. Nuvau’s principal asset is the Matagami property, located in Abitibi region of central Québec, Canada. The Matagami property was acquired from Glencore Canada Corporation on March 1, 2026, pursuant to the terms and conditions of a second amended and restated earn-in agreement dated January 28, 2026, among Nuvau, Nuvau Minerals Corp. and Glencore Canada Corporation.

Further Information

All information contained in this news release with respect to the Company was supplied by the respective party for inclusion herein, and each party and its directors and officers have relied on the other party for any information concerning the other party.

Cautionary Statements

This news release contains forward-looking statements and forward-looking information (collectively, ‘forward-looking statements‘) within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward- looking statements. Forward-looking statements are often identified by terms such as ‘may’, ‘should’, ‘anticipate’, ‘will’, ‘estimates’, ‘believes’, ‘intends’, ‘expects’ and similar expressions which are intended to identify forward-looking statements. More particularly and without limitation, this news release contains forward-looking statements concerning the proposed use of proceeds of the Offering, and the Company’s ability to obtain final exchange approval for the Offering. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company, including expectations and assumptions concerning the Company and the Matagami property. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by the management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements contained in this news release are made as of the date of this news release, and are expressly qualified by the foregoing cautionary statement. Except as expressly required by securities law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286499

(TheNewswire)

GRANDE PRAIRIE, ALBERTA TheNewswire – March 6, 2026 – Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) (‘ANGKOR’ OR ‘THE COMPANY’)  announces the completion of all final payments and closing of the sale of its 40% participating interest (the ‘Assets’) in the Evesham Macklin oil and gas lands in Saskatchewan. The transaction has received conditional approval from the TSX Venture Exchange.

As previously announced (Angkor Resources SIGNS DEFINITIVE AGREEMENT TO SELL EVESHAM OIL PRODUCTION – Angkor Resources Corp,) January 5, 2026), the Company’s wholly-owned subsidiary, EnerCam Exploration Ltd. (the ‘Vendor’), entered into an Agreement of Purchase and Sale dated December 31, 2025 (the ‘Agreement’) with 2196231 Alberta Ltd., an arm’s length party (the ‘Purchaser’), for the disposition of the Assets at a purchase price of $4,800,000.

All payments under the Agreement have now been received and deposited into the Company’s accounts, including:

(a)  a $250,000 non-refundable deposit paid on December 19, 2025;

(b)  a payment of $375,000 paid on January 30, 2026;

(c)  the balance of the Loan of $3,800,000, applied to the purchase price on closing;

(d)  a final payment of $375,000 received on March 1, 2026; and

(e)  all profit entitlements and operating and capital commitments under the Assets after October 1, 2025 have accrued to the Purchaser.

The sale of the oil and gas assets was a strategic decision that removed a debt of $3,800,000 off the books and provided the Company with $1,000,000 in net proceeds. Shareholder approval for the disposition was obtained at the Annual General and Special Meeting of Shareholders held on January 29, 2026, where over 99% of the votes cast were in favour of the transaction.

Delayne Weeks, CEO, commented ‘We are pleased to announce the successful closing of the Evesham disposition. This transaction eliminates $3,800,000 in debt and provides the Company with additional working capital. We can now focus our resources and efforts on advancing our Cambodian onshore Block VIII oil and gas project and our mineral exploration programs, which represent the highest potential for growth and value creation for our shareholders.  Discovering oil and gas in Cambodia as a new jurisdiction is a country changer. It brings energy independence to the entire nation, significantly reduces the imports of hydrocarbon based energy, and develops a very significant sector of new skillset development and employment opportunities.’

ABOUT Angkor Resources CORPORATION:

Angkor Resources Corp. is a public company, listed on the TSX-Venture Exchange, and is a leading resource optimizer in Cambodia working towards mineral and energy solutions across Cambodia.  

The company’s mineral subsidiary, Angkor Gold Corp. in Cambodia holds two mineral exploration licenses in Cambodia with multiple prospects in copper and gold.  Both licenses are in their first two-year renewal term.    

Its Cambodian energy subsidiary, EnerCam Resources, was granted an onshore oil and gas license of 7300 square kilometres in the southwest quadrant of Cambodia called Block VIII.   The company then removed all parks and protected areas and added 220 square kilometres, making the license area just over 4095 square kilometres.  EnerCam is actively advancing oil and gas exploration activities onshore to meet its mission to prove Cambodia as an oil and gas producing Nation.  Having completed seismic in 2025, the Company has identified multiple drill targets and advances an Environmental Impact Assessment and drilling plans to drill Cambodia’s first onshore oil & gas exploratory wells.

CONTACT:   Delayne Weeks – CEO

Email:-   info@angkorresources.com   Website: angkorresources.com  

Telephone: +1 (780) 831-8722

Please follow @AngkorResources on , , , Instagram and .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

_____________________________________

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. This information and these statements, referred to herein as ‘forward‐looking statements’, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the anticipated benefits of new leadership expertise, and the Company’s plans to develop its resources and create shareholder value.

In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that the Company will successfully advance the development of its resources and that such efforts will result in creating shareholder value.

These forward‐looking statements involve numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things, that the Company will not advance the development of its resources and that the Company will not create shareholder value.

Copyright (c) 2026 TheNewswire – All rights reserved.